PFG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PFG is not a strong buy right now for a beginner long-term investor, but it is a reasonable hold/watchlist name. The stock has bullish trend structure and positive momentum into pre-market, yet the RSI is very overbought and there is no Intellectia buy signal today. Given the mixed analyst stance, neutral insider/hedge activity, and cautious congress selling, the setup looks extended rather than attractive for an impatient buyer. I would not call it a clear buy at $109.69 today.
The chart is short-term bullish: MACD histogram is positive and expanding, and moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price is above pivot resistance at 105.378 and just below R1 at 108.969, with pre-market price at 109.69 already testing that area and close to R2 at 111.187. However, RSI_6 at 81.983 signals the stock is overbought, so momentum is strong but stretched. For near-term price action, the trend is upward, but the current entry is not ideal for a new long-term purchase.
["Management guidance supports roughly 9%-12% core EPS growth in 2026 across macro scenarios.", "Q1 results already reflected 13% EPS growth.", "Continued fee and product innovation in Retirement & Income Solutions.", "Disciplined pricing in Specialty Benefits.", "Solid asset management pipeline expected to support medium-term revenue growth of 4%-7%.", "Bullish technical trend with expanding MACD and stacked moving averages."]
["No news catalysts in the last week.", "RSI is overbought, making the current price extended.", "Options flow is put-heavy, indicating defensive sentiment.", "Congress trading shows 1 sale and 0 purchases in the last 90 days.", "Recent stock pattern analysis suggests only a 50% chance of modest downside moves over the next day/week/month.", "Analyst opinions are mixed, with several Neutral/Underweight views still present."]
Financial data was limited, but the latest available commentary points to a strong first quarter with 13% EPS growth and management expecting 9%-12% core EPS growth in 2026. That indicates healthy earnings momentum and decent medium-term growth, especially in Retirement & Income Solutions and Specialty Benefits. Latest quarter season: Q1.
Analyst sentiment has improved modestly, with price targets mostly being raised over the past month, including Raymond James raising to $111 and downgrading only to Outperform from Strong Buy. Even so, the Street remains mixed: Evercore is In Line, BofA is Neutral, UBS is Neutral, Barclays is Underweight, and Keefe Bruyette is Market Perform. The pros see durable EPS growth, margin discipline, and product innovation; the cons focus on sluggish premium/broker growth, cyclicality, and limited upside from here.
